Please ensure Javascript is enabled for purposes of website accessibility

Will Mallinckrodt's Xartemis Change How We Treat Pain?

By Todd Campbell – Feb 14, 2014 at 1:34PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Mallinckrodt's (MNK) pain killer drug Xartemis may give doctors a drug that's less likely to be abused than current options.

Mallinckrodt Plc (MNK) is having a stellar run since being spun-off by Covidien (COV.DL) last summer. The split-up is unlocking value at both companies as Covidien focuses on its medical device business and Mallinckrodt advances new pain killing compounds to market.  

So far, the decision to separate is paying off handsomely. Covidien's sales have marched steadily higher since Mallinckrodt's IPO, and Maillinckrodt shares have surged since November on enthusiasm surrounding its extended release oxycodone. Here's what you need to know about Mallinckrodt's Xartemis, including why it could displace current pain killers.

MNK Chart

MNK data by YCharts

Needing a better solution
Since cases of pain typically increase with age, a larger, longer living global population suggests the patient pool for pain treatment may prove bigger than diabetes, coronary heart disease, and cancer combined.

According to the Institute of Medicine, as many as 100 million Americans suffer from some form of chronic pain each year -- costing between $560 billion and $635 billion in treatment and economic loss annually.  Research from the National Center of Health Statistics estimates that 46 million Americans experience acute pain following inpatient procedures every year. 

As a result, the number of prescriptions written for pain has been soaring. Between 1999 and 2010, sales of opioid pain relieving drugs have quadrupled.  Sadly, overdoses are surging too.

The Centers for Disease Control reports that the number of prescription drug overdoses in the U.S. has tripled since 1990.  A big portion of those deaths -- nearly three of every four -- have been tied to prescription opioids, including Percocet, a brand name combination of acetaminophen and oxycodone, and Oxycontin, a drug commonly prescribed for chronic pain.

Given the risk, you might think painkillers' efficacy significantly outweighs the potential for overdose. Unfortunately, for many that's not the case. More than 50% of those suffering from chronic pain report they still have little control over their pain, and 77% of those patients report feelings of depression. Of patients having undergone surgery, 80% reported moderate to severe acute pain in the first hours to days following surgery.Those aren't the kind of numbers you want to see in a patient population being treated with drugs that are prone to misuse.

As a result, the FDA is cracking down on these drugs. They've asked drug makers to reduce levels of acetaminophen in oxycodone combinations and are likely to change the classification of hydrocodone drugs like Vicodin to schedule two, its strictest level. Oxycontin's maker, Purdue Pharma, L.P. has also shelved its original formulation for a newer version in an attempt to make it harder for people to inhale or inject it. 

Innovating existing treatments
Given widening use and abuse, drug developers are hunting for a better solution. However, results are coming up short. Avanir (NASDAQ: AVNR), for example, saw shares drop more than 40% in December when its AVP-923 pain killing candidate failed to outperform placebo in mid stage trials.

Mallinckrodt had better success in trials than Avanir and hopes its extended release combination of oxycodone and acetaminophen can win FDA support when the agency decides its fate early this year. If approved, Malllinckrodt thinks Xartemis XR could capture a big chunk of acute care acetaminophen and oxycodone scripts because Xartemis has been specially formulated to reduce user ability to abuse the drug.

That's good news for investors given opioid drugs generate billions for drug developers. Despite the risks, acetaminophen/hydrocodone is the 57th best selling drug in the U.S., with sales of more than $1 billion a year. Purdue's Oxycontin is the 19th best selling drug, with sales of more than $2 billion annually.  

What it means for the company
Malinckrodt submitted Xartemis XR to the FDA for approval for acute pain in July. Since the drug received priority review, an FDA decision and possible launch should happen between now and the end of the second quarter. Assuming the FDA green lights the drug, Xartemis will become the only extended release drug combining oxycodone with acetaminophen on the market.

An approval would be timely given that Mallinckrodt's best selling drugs, Exalgo and methylphenidate ER , or generic Concerta, will face stiffer competition this year. The two drugs helped the company's specialty drug sales climb 19% to nearly $310 million in the fourth quarter.

However, Exalgo loses patent protection this year, putting more than $100 million of Mallinckrodt's annual sales at risk. And the company's 180 day exclusivity for generic Concerta expired last year.

Fool-worthy final thoughts
Developing a new, safer pain treatment in Xartemis could mean big money for Mallinckrodt, suggesting an FDA decision on this drug may be the most important piece of news shareholders should look out for this year. If the FDA grants approval, sales will likely begin having an impact in the third quarter. Outside of Xartemis there are a few other intriguing therapies that could help offset risk of slowing sales for Exalgo and generic Concerta, including Pennsaid and MNK-155. But their opportunity is more muted than Xartemis'.

Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned.  Todd also owns Gundalow Advisors, LLC.  Gundalow's clients do not have positions in the companies mentioned. The Motley Fool recommends Covidien. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Nearly 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Mallinckrodt Stock Quote
Covidien plc Stock Quote
Covidien plc

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.